<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Valproate preparations for agitation in dementia - Baillon, SF - 2018 | Cochrane Library</title> <meta content="Valproate preparations for agitation in dementia - Baillon, SF - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003945.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Valproate preparations for agitation in dementia - Baillon, SF - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003945.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003945.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Valproate preparations for agitation in dementia" name="citation_title"/> <meta content="Sarah F Baillon" name="citation_author"/> <meta content="Usha Narayana" name="citation_author"/> <meta content="Leeds and York Partnerships NHS Foundation Trust" name="citation_author_institution"/> <meta content="Jay S Luxenberg" name="citation_author"/> <meta content="On Lok" name="citation_author_institution"/> <meta content="Andrew V Clifton" name="citation_author"/> <meta content="De Montfort University" name="citation_author_institution"/> <meta content="andrew.clifton@dmu.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD003945.pub4" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003945.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003945.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003945.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aggression [drug effects]; Antimanic Agents [adverse effects, *therapeutic use]; Cognition [drug effects]; Dementia [*complications]; Psychomotor Agitation [*drug therapy, etiology]; Randomized Controlled Trials as Topic; Treatment Outcome; Valproic Acid [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003945.pub4&amp;doi=10.1002/14651858.CD003945.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003945\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003945\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fr","ja","fa","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003945.pub4",title:"Valproate preparations for agitation in dementia",firstPublishedDate:"Oct 5, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003945.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003945.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003945.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003945.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003945.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003945.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003945.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003945.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003945.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003945.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6060 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003945.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/appendices#CD003945-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/table_n/CD003945StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/table_n/CD003945StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Valproate preparations for agitation in dementia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information#CD003945-cr-0002">Sarah F Baillon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information#CD003945-cr-0003">Usha Narayana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information#CD003945-cr-0004">Jay S Luxenberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information#CD003945-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Andrew V Clifton</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information/en#CD003945-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003945.pub4">https://doi.org/10.1002/14651858.CD003945.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003945-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003945-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003945-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003945-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003945-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003945-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003945-abs-0001" lang="en"> <section id="CD003945-sec-0001"> <h3 class="title" id="CD003945-sec-0001">Background</h3> <p>Agitation has been reported in up to 90% of people with dementia. Agitation in people with dementia worsens carer burden, increases the risk of injury, and adds to the need for institutionalisation. Valproate preparations have been used in an attempt to control agitation in dementia, but their safety and efficacy have been questioned. </p> </section> <section id="CD003945-sec-0002"> <h3 class="title" id="CD003945-sec-0002">Objectives</h3> <p>To determine the efficacy and adverse effects of valproate preparations used to treat agitation in people with dementia, including the impact on carers. </p> </section> <section id="CD003945-sec-0003"> <h3 class="title" id="CD003945-sec-0003">Search methods</h3> <p>We searched <a href="http://www.medicine.ox.ac.uk/alois" target="_blank">ALOIS</a> – the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 7 December 2017 using the terms: valproic OR valproate OR divalproex. ALOIS contains records from all major health care databases (the Cochrane Library, MEDLINE, Embase, PsycINFO, CINAHL, LILACS) as well as from many trials databases and grey literature sources. </p> </section> <section id="CD003945-sec-0004"> <h3 class="title" id="CD003945-sec-0004">Selection criteria</h3> <p>Randomised, placebo‐controlled trials that assessed valproate preparations for agitation in people with dementia. </p> </section> <section id="CD003945-sec-0005"> <h3 class="title" id="CD003945-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the retrieved studies against the inclusion criteria and extracted data and assessed methodological quality of the included studies. If necessary, we contacted trial authors to ask for additional data, including relevant subscales, or for other missing information. We pooled data in meta‐analyses where possible. This is an update of a Cochrane Review last published in 2009. We found no new studies for inclusion. </p> </section> <section id="CD003945-sec-0006"> <h3 class="title" id="CD003945-sec-0006">Main results</h3> <p>The review included five studies with 430 participants. Studies varied in the preparations of valproate, mean doses (480 mg/day to 1000 mg/day), duration of treatment (three weeks to six weeks), and outcome measures used. The studies were generally well conducted although some methodological information was missing and one study was at high risk of attrition bias. </p> <p>The quality of evidence related to our primary efficacy outcome of agitation varied from moderate to very low. We found moderate‐quality evidence from two studies that measured behaviour with the total Brief Psychiatric Rating Scale (BPRS) score (range 0 to 108) and with the BPRS agitation factor (range 0 to 18). They found that there was probably little or no effect of valproate treatment over six weeks (total BPRS: mean difference (MD) 0.23, 95% confidence interval (CI) –2.14 to 2.59; 202 participants, 2 studies; BPRS agitation factor: MD –0.67, 95% CI –1.49 to 0.15; 202 participants, 2 studies). Very low‐quality evidence from three studies which measured agitation with the Cohen‐Mansfield Agitation Index (CMAI) were consistent with a lack of effect of valproate treatment on agitation. There was variable quality evidence on other behaviour outcomes reported in single studies of no difference between groups or a benefit for the placebo group. </p> <p>Three studies, which measured cognitive function using the Mini‐Mental State Examination (MMSE), found little or no effect of valproate over six weeks, but we were uncertain about this result because the quality of the evidence was very low. Two studies that assessed functional ability using the Physical Self‐Maintenance Scale (PSMS) (range 6 to 30) found that there was probably slightly worse function in the valproate‐treated group, which was of uncertain clinical importance (MD 1.19, 95% CI 0.40 to 1.98; 203 participants, 2 studies; moderate‐quality evidence). </p> <p>Analysis of adverse effects and serious adverse events (SAE) indicated a higher incidence in valproate‐treated participants. A meta‐analysis of three studies showed that there may have been a higher rate of adverse effects among valproate‐treated participants than among controls (odds ratio (OR) 2.02, 95% CI 1.30 to 3.14; 381 participants, 3 studies, low‐quality evidence). Pooled analysis of the number of SAE for the two studies that reported such data indicated that participants treated with valproate preparations were more likely to experience SAEs (OR 4.77, 95% CI 1.00 to 22.74; 228 participants, 2 studies), but the very low quality of the data made it difficult to draw any firm conclusions regarding SAEs. Individual adverse events that were more frequent in the valproate‐treated group included sedation, gastrointestinal symptoms (nausea, vomiting, and diarrhoea), and urinary tract infections. </p> </section> <section id="CD003945-sec-0007"> <h3 class="title" id="CD003945-sec-0007">Authors' conclusions</h3> <p>This updated review corroborates earlier findings that valproate preparations are probably ineffective in treating agitation in people with dementia, but are associated with a higher rate of adverse effects, and possibly of SAEs. On the basis of this evidence, valproate therapy cannot be recommended for management of agitation in dementia. Further research may not be justified, particularly in light of the increased risk of adverse effects in this often frail group of people. Research would be better focused on effective non‐pharmacological interventions for this patient group, or, for those situations where medication may be needed, further investigation of how to use other medications as effectively and safely as possible. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003945-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003945-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003945-abs-0014">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003945-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003945-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003945-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003945-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003945-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003945-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003945-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003945-abs-0005" lang="en"> <h3>Valproate preparations for the treatment of agitated behaviour in people with dementia</h3> <p><b>Background</b> </p> <p>Agitated behaviour is very common in the later stages of dementia. It can include verbal behaviours, such as shouting, and physical behaviours, such as wandering or physical aggression. It has been shown to worsen the stress experienced by family carers, increase the risk of injury, and increase the need for people with dementia to move into institutional care. </p> <p>A type of medication that has been used to treat agitated behaviour in people who have dementia is valproate, which is available in several different preparations (valproic acid, divalproex sodium, sodium valproate, and valproate semi‐sodium). These medications are not recommended in current guidelines (e.g. from the National Institute for Health and Care Excellence), but are sometimes still given to people with dementia to treat agitated behaviour. </p> <p><b>Purpose of this review</b> </p> <p>We wanted to review the evidence about how effective and safe it is to give valproate preparations to people with dementia to treat agitation. </p> <p><b>Studies included in this review</b> </p> <p>We searched medical databases up to December 2017 for studies that compared any preparation of valproate with a placebo (dummy tablet) to treat agitated behaviour in people diagnosed with dementia. </p> <p>We included five studies with 479 participants who had various types of dementia and agitated behaviour. Most studies lasted for six weeks, although one was only three weeks long. The studies were generally well conducted, but the methods were not always fully reported and one study was at high risk of bias because of the high number of people who dropped out from the valproate‐treated group. </p> <p><b>Key findings</b> </p> <p>Studies measured agitated behaviour with various scales and the reliability of the evidence for the different scales ranged from moderate to very low. Overall, we found no evidence that valproate preparations improved behaviour, or specifically, agitated behaviour. We found that valproate preparations probably had little or no effect on participants' ability to perform daily activities. We could not be sure whether they had an effect on cognition (thinking and remembering) because the reliability of the evidence was very low. </p> <p>We found low‐reliability evidence from three studies that participants taking valproate may be more likely than those taking placebo to experience harmful effects. We could not be as certain about differences in serious harms, such as serious illness or admission to hospital, but data from two studies suggested that these may be more common in the participants taking valproate. Some of the side effects associated with valproate were sleepiness, feeling sick, being sick, watery stools, and urinary tract infections. </p> <p><b>Conclusions</b> </p> <p>We only identified five relatively small studies for inclusion in this review. They varied in their methods, type of medicine and its dose, duration of treatment, and scales used to make measurements. This limited our ability to pool data across studies. However, we could be moderately confident in the conclusion that valproate preparations do not improve agitated behaviour in dementia. They may also be associated with harmful effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003945-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003945-sec-0106"></div> <h3 class="title" id="CD003945-sec-0107">Implications for practice</h3> <section id="CD003945-sec-0107"> <p>Robust randomised controlled trial evidence regarding valproate preparations for aggression in people who have dementia is limited, and we identified only five studies for inclusion in this review. Evidence from the five trials, including limited pooled analysis of data, did not support the use of valproate preparations to manage agitation in people with dementia, and demonstrated increased frequency of several types of adverse effect, including serious adverse effects. </p> <p>From the information available, valproate preparations cannot be recommended for the treatment of people with dementia with agitation. </p> </section> <h3 class="title" id="CD003945-sec-0108">Implications for research</h3> <section id="CD003945-sec-0108"> <p>The quality of evidence in this review ranged from moderate to very low on a range of different outcome measures and overall did not indicate any benefit of valproate for the treatment of agitation in people with dementia. As the limited evidence that was available showed no signal of benefit, further investigation may not be justified, particularly in light of the increased risk of adverse effects in this often frail group of people. Research would be better focused on effective non‐pharmacological interventions for this patient group, or, for those situations where the behaviours present immediate risk, further evaluation of how other medications, such as antipsychotics, can be used most effectively and safely. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003945-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003945-sec-0036"></div> <div class="table" id="CD003945-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Valproate preparations compared to placebo for agitation in dementia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Valproate preparations compared to placebo for agitation in dementia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with agitation in dementia<br/> <b>Setting:</b> <br/> <b>Intervention:</b> valproate preparations<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with valproate preparations</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Agitation and aggression</b><br/> assessed with: Brief Psychiatric Rating Scale total score. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 0–108 (higher score indicated higher level of dysfunction)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for agitation and aggression was –5.34 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.23 higher<br/> (2.14 lower to 2.59 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Agitation and aggression</b><br/> assessed with: BPRS agitation factor. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 0–18 (higher score indicated higher level of dysfunction)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for agitation and aggression was –1.88 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.67 lower<br/> (1.49 lower to 0.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Agitation and aggression</b><br/> assessed with: Cohen‐Mansfield Agitation Index total score. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 0–216 (higher score indicated more agitated behaviour)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for agitation and aggression was –4.42 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.84 lower<br/> (6.02 lower to 2.34 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition</b><br/> assessed with: Mini‐Mental State Examination total score. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 0–30 (lower score indicated greater cognitive impairment)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for cognition was 0.46 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.7 lower<br/> (1.61 lower to 0.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional performance</b><br/> assessed with: Physical Self‐Maintenance Scale total score. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 6–30 (higher score indicated greater impairment in ADL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for functional performance was 0.06 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.19 higher<br/> (0.4 higher to 1.98 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Any adverse event</b> by 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 2.02</b><br/> (1.30 to 3.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>381<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>602 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>753 per 1000<br/> (663 to 826) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> by 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 4.77</b><br/> (1.00 to 22.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/> (18 to 291) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADL:</b> activities of daily living; <b>CI:</b> confidence interval; <b>ITT:</b> intention to treat; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision due to small number of participants. </p> <p><sup>b</sup>Downgraded in light of imprecision due to confidence intervals including the potential for harm or benefit. </p> <p><sup>c</sup>Downgraded one level due to inconsistency (heterogeneity between studies). </p> <p><sup>d</sup>Downgraded one level due to study limitations (risk of bias). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003945-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003945-sec-0037"></div> <section id="CD003945-sec-0038"> <h3 class="title" id="CD003945-sec-0038">Description of the condition</h3> <p>Agitation is reported in up to 90% of people with dementia (<a href="./references#CD003945-bbs2-0022" title="Alzheimer's Society. Optimising Treatment and Care for People with Behavioural and Psychological Symptoms of Dementia: a Best Practice Guide for Health and Social Care Professionals. London: Alzheimer's Society, 2011. ">Alzheimer's Society 2011a</a>). A widely accepted definition of agitation is: "inappropriate verbal, vocal, or motor activity that is not explained by needs or confusion per se" (<a href="./references#CD003945-bbs2-0029" title="BilligN , Cohen‐MansfieldJ , LipsonS . Pharmaceutical treatment of agitation in a nursing home. Journal of the American Geriatrics Society1991;39:1002‐5. ">Billig 1991</a>; <a href="./references#CD003945-bbs2-0031" title="Cohen‐MansfieldJ , WernerP , MarxMS . An observational study of agitation in agitated nursing home residents. International Psychogeriatrics1989;1:153‐65. ">Cohen‐Mansfield 1989</a>). The descriptors of agitation include wandering, crying out, aggressiveness, repetitive movements, and unco‐operative behaviour. Agitation in people with dementia worsens carer burden, increases the risk of injury, and adds to the need for institutionalisations (<a href="./references#CD003945-bbs2-0041" title="LivingstonG , KellyL , Lewis‐HolmesE , BaioG , MorrisS , PatelN , et al. Non‐pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. British Journal of Psychiatry2014;205(6):436‐42. ">Livingstone 2014</a>). </p> </section> <section id="CD003945-sec-0039"> <h3 class="title" id="CD003945-sec-0039">Description of the intervention</h3> <p>Current guidelines recommend that people with dementia who develop non‐cognitive symptoms or behaviours that cause them distress or challenge those who provide their care should first have a comprehensive assessment to determine likely causative factors, such as physical illness, depression, pain, adverse effects of medication, personal or psychosocial factors, or aspects of their physical environment. Appropriate steps should then be taken to address those factors, and a period of 'watchful waiting' should be observed, if possible, as in many cases symptoms will improve or resolve over four to six weeks (<a href="./references#CD003945-bbs2-0022" title="Alzheimer's Society. Optimising Treatment and Care for People with Behavioural and Psychological Symptoms of Dementia: a Best Practice Guide for Health and Social Care Professionals. London: Alzheimer's Society, 2011. ">Alzheimer's Society 2011a</a>). The guidelines also suggest that consideration should be given to providing individualised interventions such as aromatherapy or multisensory stimulation as there is some evidence of their clinical effectiveness (<a href="./references#CD003945-bbs2-0041" title="LivingstonG , KellyL , Lewis‐HolmesE , BaioG , MorrisS , PatelN , et al. Non‐pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. British Journal of Psychiatry2014;205(6):436‐42. ">Livingstone 2014</a>; <a href="./references#CD003945-bbs2-0046" title="National Institute for Health and Care Excellence. Dementia: Supporting People with Dementia and their Carers in Health and Social Care. Clinical guideline CG42. London: National Institute of Health and Care Excellence, 2006. ">NICE 2006</a>). In fact, research has shown that just 10 minutes of one‐to‐one time each day can reduce behavioural and psychological symptoms associated with dementia (BPSD) (<a href="./references#CD003945-bbs2-0023" title="Alzheimer's Society. Reducing the Use of Anti‐psychotic Drugs: a Guide to the Treatment and Care of Behavioural and Psychological Symptoms of Dementia. London: Alzheimer's Society, 2011. ">Alzheimer's Society 2011b</a>). </p> <p>The National Institute for Health and Care Excellence (NICE) guideline on supporting people with dementia and their carers suggests that people with dementia who present with non‐cognitive symptoms or challenging behaviour should be offered pharmacological intervention in the first instance "only if they are severely distressed or there is an immediate risk of harm to the person or others" and that a thorough assessment of possible causes of the behaviour should be carried out as soon as possible (<a href="./references#CD003945-bbs2-0048" title="National Institute for Health and Care Excellence. Dementia: Supporting People with Dementia and their Carers in Health and Social Care. Updated Clinical guideline CG42. London: National Institute for Health and Care Excellence, 2016. ">NICE 2016</a>). Drug treatment for the control of violence, aggression, and extreme agitation should be implemented with the aim of avoiding sedation and the use of high doses or combinations of drugs, and with careful monitoring of the person's physical condition and any adverse effects (<a href="./references#CD003945-bbs2-0046" title="National Institute for Health and Care Excellence. Dementia: Supporting People with Dementia and their Carers in Health and Social Care. Clinical guideline CG42. London: National Institute of Health and Care Excellence, 2006. ">NICE 2006</a>). </p> <p>If drug treatment of agitation is considered necessary, then the drug classes recommended by NICE, in order, are antipsychotics, acetylcholinesterase inhibitors, and memantine. There is some evidence of modest benefits of antipsychotics in around 50% of people with dementia, but they are associated with adverse effects such as sedation, parkinsonism, gait disturbance, dehydration, falls, chest infection, accelerated cognitive decline, and stroke, and they are associated with increased mortality in the long term (<a href="https://www.archie.cochrane.org/sections/documents/view?version=z1708221409413896468061181951993%26format=REVMAN#REF-Alzheimer_x005F_x005F_x0027_s-Society-2011b" target="_blank">Alzheimer's Society 2011b</a>; <a href="./references#CD003945-bbs2-0043" title="MaherAR , MaglioneM , BagleyS , SuttorpM , HuJH , EwingB , et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off‐label uses in adults: a systematic review and meta‐analysis. Journal of the American Medical Association2011;306:1359‐69. ">Maher 2011</a>). The increased risk of cerebrovascular adverse events and death in this patient group resulted in a Medicines and Healthcare products Regulatory Agency (MHRA) warning that no antipsychotic should be used for this indication in dementia (except risperidone in some circumstances) (<a href="./references#CD003945-bbs2-0045" title="Medicines and Healthcare products Regulatory Agency. Antipsychotics: initiative to reduce prescribing to older people with dementia. Drug Safety Update2012;5(10):H1. ">MHRA 2012</a>). Risperidone is the only antipsychotic licensed for people with dementia, and guidelines recommend treatment should be used for no longer than 12 weeks. The evidence of benefit of other types of antipsychotics is more limited, and use for BPSD is off‐label. Acetylcholinesterase inhibitors and memantine are licensed for the treatment of cognitive symptoms in Alzheimer's disease and there is some evidence that these medications may positively impact on agitated behaviour, although there is no evidence that they specifically improve agitation (<a href="https://www.archie.cochrane.org/sections/documents/view?version=z1708221409413896468061181951993%26format=REVMAN#REF-NICE-2006" target="_blank">NICE 2006</a>). </p> <p>Other medications that have been used to treat agitated behaviour in people with dementia include benzodiazepines, hypnotics, antidepressants, and anticonvulsants. There is no evidence of benefit of benzodiazepines for this indication, and they carry increased risk of adverse effects (<a href="./references#CD003945-bbs2-0028" title="BiermanEJ , ComijsHC , GundyCM , SonnenbergC , JonkerC , BeekmanAT . The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent?. International Journal of Geriatric Psychiatry2007;22:1194‐200. ">Bierman 2007</a>). There is relatively little evidence relating to antidepressants for agitated behaviour in dementia; findings on efficacy are mixed and there is evidence of adverse effects (<a href="./references#CD003945-bbs2-0052" title="PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Journal of the American Medical Association2014;311:682‐91. ">Porteinsson 2014</a>; <a href="./references#CD003945-bbs2-0055" title="SeitzD , AdunuriN , GillSS , GruneirA , HerrmannN , RochonP . Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD008191.pub2] ">Seitz 2011</a>). Among anticonvulsants, carbamazepine and valproate preparations have both been used widely. </p> </section> <section id="CD003945-sec-0040"> <h3 class="title" id="CD003945-sec-0040">How the intervention might work</h3> <p>Various valproate preparations are available: valproic acid, divalproex, sodium valproate, and valproate semi‐sodium. Suggested mechanisms by which valproic acid may have an impact on agitation include enhancement of the intracerebral neurotransmitting agent, gamma‐butyric acid (GABA), antimanic action, and mood stabilising effect (<a href="./references#CD003945-bbs2-0042" title="LonAD , McElroySL , KeysMA . Valproate in the treatment of behavioral agitation in elderly patients with dementia. Journal of Neuropsychiatry and Clinical Neurosurgery1995;7:314‐9. ">Lon 1995</a>). Since 1996, a more readily tolerated compound of valproate, divalproex, has been used. This drug differs slightly from valproic acid in that peak blood flow levels occur later (three to six hours, compared with three hours), but the dosage and half‐life of this drug are identical to those of valproic acid. Sodium valproate is licensed for the treatment of epilepsy in standard‐release oral preparations, and in modified‐released preparations for various indications according to the preparation. Sodium valproate or valproate semi‐sodium is licensed for the treatment of manic episodes in bipolar disorder. None of the valproate preparations are licensed for the management of agitated behaviour in people with dementia; therefore, use of for this purpose is off‐label. </p> <p>Adverse effects associated with valproate preparations include falls, gait disturbances, sedation, tremor, muscular weakness, depressed mood, gastrointestinal disorders (nausea, vomiting, constipation, and diarrhoea), urinary tract infections (UTI), and thrombocytopenia. The current NICE advice on the use of valproate preparations for the management of aggression, agitation, and behavioural disturbances in dementia states that current evidence suggests that such medications are no more effective than placebo, and that adverse effects are also more common in people taking them (<a href="https://www.archie.cochrane.org/sections/documents/view?version=z1708221409413896468061181951993%26format=REVMAN#REF-NICE-2015" target="_blank">NICE 2015</a>). </p> </section> <section id="CD003945-sec-0041"> <h3 class="title" id="CD003945-sec-0041">Why it is important to do this review</h3> <p>This is an update of a Cochrane Review first published in 2004, and previously updated in 2009. </p> <p>One summary of evidence published by NICE suggests that valproate preparations are no more effective than placebo for agitation in dementia (<a href="https://www.archie.cochrane.org/sections/documents/view?version=z1708221409413896468061181951993%26format=REVMAN#REF-NICE-2015" target="_blank">NICE 2015</a>). Despite this guidance, valproate preparations are still sometimes being used in this patient group, perhaps because other drug options are not always effective and may be associated with adverse effects. This update is intended to apply current Cochrane methods to synthesise the evidence concerning use of valproate for agitation in dementia, and to assess the quality of this evidence, in order to inform decision‐making by carers, clinicians, researchers, and policy‐makers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003945-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003945-sec-0042"></div> <p>To determine the efficacy and adverse effects of valproate preparations used to treat agitation in people with dementia, including the impact on carers. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003945-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003945-sec-0043"></div> <section id="CD003945-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003945-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included only randomised, placebo‐controlled trials. We excluded interrupted time series trials. Where studies used a cross‐over design, we included only data from the first part of the study. </p> </section> <section id="CD003945-sec-0046"> <h4 class="title">Types of participants</h4> <p>We included participants of either sex and of any age, both inpatients and outpatients (with or without carers). Dementia should have been diagnosed according to the classifications provided by Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM‐IV) (<a href="./references#CD003945-bbs2-0026" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington (DC): American Psychiatric Publishing, 1994. ">APA 1994</a>), International Classification of Diseases, 10th edition (ICD‐10) (<a href="./references#CD003945-bbs2-0057" title="World Health Organization. ICD‐10. Tenth Revision of the International Classification of Diseases. Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. 10th Edition. Geneva: World Health Organization, 1991. ">WHO 1991</a>), Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSM‐III) (<a href="./references#CD003945-bbs2-0024" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington (DC): American Psychiatric Association, 1980. ">APA 1980</a>), or Diagnostic and Statistical Manual of Mental Disorders, 3rd revised edition (DSM‐IIIR) (<a href="./references#CD003945-bbs2-0025" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington (DC): American Psychiatric Publishing, 1987. ">APA 1987</a>). In the absence of these criteria, we also accepted other evidence of dementia such as the Mini‐Mental State Examination (MMSE) (<a href="./references#CD003945-bbs2-0036" title="FolsteinMF , FolsteinSE , McHughPR . A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189‐98. ">Folstein 1975</a>), psychiatric evaluation, psychological evaluation, or a medical evaluation. We accepted definitions of agitation provided by individual investigators. </p> <p>Because agitation is common in delirium, we had initially specified that all studies should have included clinical evaluation to rule out delirium and other treatable causes of agitation (e.g. pain, infection, drug effect, urinary or faecal retention) prior to entering people into the trial. However, reporting of baseline clinical evaluation was not always specific or detailed. Therefore, we took a pragmatic approach to avoid risking the loss of relevant evidence and included studies despite this information not being explicitly reported. </p> </section> <section id="CD003945-sec-0047"> <h4 class="title">Types of interventions</h4> <p>We required at least one week of treatment with valproate preparations, of any dosage given by mouth, compared with placebo. People receiving stable therapy with other psychoactive medications, including cholinesterase inhibitors, memantine, and antidepressants, could be included if this was permitted in the study protocol. </p> </section> <section id="CD003945-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD003945-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003945-list-0001"> <li> <p>Agitation, or one or more aspects of agitation as measured by a scale that specifically measured agitation, either exclusively or as one of its components. The scales included but were not limited to: </p> </li> </ul> <ul class="plain" id="CD003945-list-0002"> <li> <ul id="CD003945-list-0003"> <li> <p>Cohen‐Mansfield Agitation Inventory (CMAI; <a href="./references#CD003945-bbs2-0030" title="Cohen‐MansfieldJ , BilligN . Agitated behaviours in the elderly. 1. A conceptual review. Journal of the American Geriatrics Society1986;34:711‐21. ">Cohen‐Mansfield 1986</a>); </p> </li> <li> <p>Social Dysfunction and Agitation Scale (SDAS; <a href="./references#CD003945-bbs2-0058" title="WistedtB , RasmussenA , PedersenL , MalmU , Träskman‐BendzL , WakelinJ , et al. The development of an observer‐scale for measuring social dysfunction and aggression. Pharmacopsychiatry1990;23:249‐52. ">Wistedt 1990</a>); </p> </li> <li> <p>Clinical Global Impression Scale for Aggression (CGI; <a href="./references#CD003945-bbs2-0037" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. USA Department of Health, Education and Welfare Publication (ADM) 76‐338. 2nd Edition. Washington (DC): US Government Printing Office, 1976:218‐22. ">Guy 1976</a>); </p> </li> <li> <p>"Nurse Observation" scale (<a href="./references#CD003945-bbs2-0032" title="ColendaCC , HamerRM . Antecedents and interventions for aggressive behavior of patients at a geropsychiatric state hospital. Hospital and Community Psychiatry1991;42:287‐92. ">Colenda 1991</a>); </p> </li> <li> <p>Behavior Observation Scale of Intramural Psychogeriatric Patients (GIP; <a href="./references#CD003945-bbs2-0056" title="VerstratenPF . The GIP: an observational ward behavior scale. Psychopharmacology Bulletin1988;24:717‐9. ">Verstraten 1988</a>); </p> </li> <li> <p>Brief Psychiatric Rating Scale (BPRS; <a href="./references#CD003945-bbs2-0049" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychology Reports1962;10:799‐812. ">Overall 1962</a>; <a href="./references#CD003945-bbs2-0050" title="OverallJ , GorhamD . Introduction: the Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacology Bulletin1988;24:97‐8. ">Overall 1988</a>); </p> </li> <li> <p>Overt Aggression Scale (OAS; <a href="./references#CD003945-bbs2-0059" title="YudofskySC , SilverJM , JacksonW , EndicottJ , WilliamsD . The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry1986;143:35‐9. ">Yudofsky 1986</a>). </p> </li> </ul> </li> </ul> </p> </section> <section id="CD003945-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003945-list-0004"> <li> <p>Cognition.</p> </li> <li> <p>Functional performance.</p> </li> <li> <p>Overall clinical impression.</p> </li> <li> <p>Effect on carers (carers' psychological morbidity or burden).</p> </li> <li> <p>Incidence and severity of adverse effects.</p> </li> <li> <p>Dropouts, including dropouts due to adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD003945-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003945-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>), which is the Cochrane Dementia and Cognitive Improvement Group's (CDCIG) Specialized Register on 2 October 2014. The search terms used were: valproic OR valproate OR divalproex. </p> <p>The Information Specialists for the CDCIG maintain ALOIS, which contains studies that fall within the areas of dementia prevention, dementia treatment and management, and cognitive enhancement in healthy older populations. The studies are identified through: </p> <p> <ul id="CD003945-list-0005"> <li> <p>monthly searches of a number of major healthcare databases: MEDLINE, Embase, CINAHL, PsycINFO, and Lilacs; </p> </li> <li> <p>monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial Register); the World Health Organization (WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others); </p> </li> <li> <p>quarterly searches of the Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>six‐monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses and Australasian Digital Theses. </p> </li> </ul> </p> <p>To view a list of all sources searched for ALOIS see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>). </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL, and conference proceedings can be viewed in the 'methods used in reviews' section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <section id="CD003945-sec-0053"> <h5 class="title">Searching other resources</h5> <p>We performed additional searches in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up‐to‐date and as comprehensive as possible. The search strategies used can be seen in <a href="./appendices#CD003945-sec-0112">Appendix 1</a>. </p> <p>We carried out the most recent search for this review on 7 December 2017. Previous searches were done in October 2016, July 2010, and February 2008. </p> </section> </section> </section> <section id="CD003945-sec-0054"> <h3 class="title" id="CD003945-sec-0054">Data collection and analysis</h3> <section id="CD003945-sec-0055"> <h4 class="title">Selection of studies</h4> <p>The Information Specialist of the CDCIG removed duplicates of the same references. Two review authors (ETL and JL) independently examined titles and abstracts against the prespecified inclusion criteria to exclude clearly ineligible studies. We examined any potentially eligible trial in full text. Two review authors (ETL and JL) independently evaluated full texts according to the eligibility criteria. We compared selections of trials and the review authors agreed the final list of studies. We explained final decisions for the exclusion of articles that we retrieved in full text in the <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009002.pub3/full#CD009002-sec2-0020" target="_blank">Characteristics of excluded studies</a> table. </p> </section> <section id="CD003945-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (ETL and JL) extracted data from each study using a data collection form that was piloted by the team. For the purpose of this updated review, the data were entered into Review Manager 5 (<a href="./references#CD003945-bbs2-0053" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Two review authors (AC and SFB) checked the data for accuracy. We also extracted data about ongoing studies, including study name, methods, participants, interventions, outcomes, starting date, contact information, and notes. </p> </section> <section id="CD003945-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SFB and AC) independently assessed the risk of bias in accordance with Cochrane's tool for assessing methodological quality and risk of bias (<a href="./references#CD003945-bbs2-0038" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). This tool assesses how the randomisation sequence was generated, how allocation was concealed, the integrity of blinding (participants, raters, and personnel), the completeness of outcome data, selective reporting, and other biases. Where inadequate details of randomisation and other characteristics of the trials were provided, we contacted authors of the studies to obtain further information. </p> <p>We described the risk of bias of all included studies in the <a href="./references#CD003945-sec-0122" title="">Characteristics of included studies</a> table and narratively. In addition, we provided an overall judgement of included studies in a 'Risk of bias' summary (see <a href="#CD003945-fig-0001">Figure 1</a>). Where the two review authors disagreed on 'Risk of bias' decisions, the final rating was made by consensus discussion involving the third member of the review team. </p> <div class="figure" id="CD003945-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003945-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD003945-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We used the mean difference (MD) to measure the treatment effect. If the same outcome was assessed using different scales, then we used the standardised mean difference (SMD). We reported 95% confidence intervals (CI). We reported results of dichotomous outcomes as odds ratios (OR) with 95% CI. </p> </section> <section id="CD003945-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>We considered only participant‐level outcomes. We analysed change in outcome measure from pre‐ to post‐treatment. For cross‐over trials, we used data for the first period only (if available) because of the possibility of carry‐over effects. </p> </section> <section id="CD003945-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>To allow an intention‐to‐treat analysis, we sought data irrespective of compliance, whether or not the participant was subsequently deemed ineligible, or otherwise excluded from treatment or follow‐up. If intention‐to‐treat data were not available in the publications, we extracted 'on‐treatment' data or the data of participants who completed the trial and indicated it as such. We did not use data from titration phases prior to the randomised phase to assess safety or efficacy. </p> </section> <section id="CD003945-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered clinical heterogeneity between trials (participants, interventions, and outcomes) when deciding whether or not to synthesise data. Where we performed a meta‐analysis, we used a standard Chi<sup>2</sup> test to check for heterogeneity. We also assessed the impact of heterogeneity on the meta‐analysis using the I<sup>2</sup> statistic. </p> </section> <section id="CD003945-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to minimise the impact of publication bias by searching for both published and unpublished trials. We compared conference abstracts and registered trials with published data. We contacted the responsible organisation or the researcher for more information when we found studies in trial registries that appeared to have been completed but not published (see <a href="#CD003945-sec-0068">Description of studies</a>). We found too few studies to allow assessment of possible publication bias using funnel plots and Egger's test for asymmetry (<a href="./references#CD003945-bbs2-0035" title="EggerM , SmithG D , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997:315:629. [https://doi.org/10.1136/bmj.315.7109.629 ] ">Egger 1997</a>). </p> </section> <section id="CD003945-sec-0063"> <h4 class="title">Data synthesis</h4> <p>Where data were suitable for a meta‐analysis, we presented the effect estimate from a fixed‐effect model. </p> </section> <section id="CD003945-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Due to the low number of included studies, subgroup analysis was not possible. Therefore, participants were combined into the category of 'dementia' regardless of subtype. </p> </section> <section id="CD003945-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We did not conduct any sensitivity analyses.</p> <section id="CD003945-sec-0066"> <h5 class="title">'Summary of findings' table</h5> <p>We used the GRADE approach to assess the quality of the supporting evidence behind each estimate of treatment effect. We presented key outcomes in <a href="./full#CD003945-tbl-0001">summary of findings Table for the main comparison</a>, including, for each outcome, a summary of the amount of data, the magnitude of the effect size, and the overall quality of the evidence (<a href="./references#CD003945-bbs2-0054" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). The measures included were: change in agitation and aggression, cognition, functional performance, and incidence and severity of adverse effects. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003945-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003945-sec-0067"></div> <section id="CD003945-sec-0068"> <h3 class="title">Description of studies</h3> <section id="CD003945-sec-0069"> <h4 class="title">Results of the search</h4> <p>The initial search for eligible RCTs was completed in August 2005. This identified three studies for inclusion in the review (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>). An updated search on 7 February 2008 retrieved two new studies (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). Further updated searches on 30 July 2010, and 4 November 2016 identified no new studies for either inclusion or exclusion in the review. The most recent search was performed in December 2017. </p> <p>After removal of duplicates and first assessment by the Information Specialist of the CDCIG based on a screening of titles and abstracts, these searches resulted in a total of 41 records being passed to the authors for further scrutiny. </p> <p>See <a href="#CD003945-fig-0002">Figure 2</a> for the flow of studies for this review. </p> <div class="figure" id="CD003945-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003945-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003945-sec-0070"> <h4 class="title">Included studies</h4> <p>We identified five studies eligible for inclusion (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). A detailed description of each study is given in the <a href="./references#CD003945-sec-0122" title="">Characteristics of included studies</a> table. </p> <section id="CD003945-sec-0071"> <h5 class="title">Design</h5> <p>Two studies were placebo‐controlled crossover studies (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>). In <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>, there were two three‐week treatment periods separated by a one‐week washout period. In <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>, the treatment periods lasted six weeks and there was a two‐week washout period between treatments. The remaining three studies were parallel‐group, placebo‐controlled RCTs with six‐week treatment periods (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). </p> </section> <section id="CD003945-sec-0072"> <h5 class="title">Sample size</h5> <p>The two crossover studies were the smallest with 14 (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>) and 43 (<a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>) participants. <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> had 56 participants, <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> had 173, and <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> had 153. </p> </section> <section id="CD003945-sec-0073"> <h5 class="title">Setting</h5> <p>One study was conducted in Europe (<a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>), and another in Canada (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>). Three were multisite studies in the US (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). All studies involved people who were institutionalised. In <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>, the participants were from a short‐stay ward at a psychiatric hospital; in the other studies, participants were resident in long‐term care facilities. </p> </section> <section id="CD003945-sec-0074"> <h5 class="title">Participants</h5> <p>See <a href="#CD003945-tbl-0002">Table 1</a> for a description of the participants' characteristics at baseline in all studies. </p> <div class="table" id="CD003945-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% Women</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnoses and baseline assessments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean MMSE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentric, institutionalised; Alzheimer's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valproate (n = 14)</p> <p>Placebo (n = 13)</p> <p>Valproate titrated to 1500 mg/day</p> <p>6‐week course</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD: NINDCDS‐ADRDA criteria</p> <p>Agitation/aggression: CMAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentric, institutionalised; AD, VaD, and other dementias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valproic acid (n = 28)</p> <p>Placebo (n = 28).</p> <p>Divalproex sodium titrated to mean 826 mg/day</p> <p>6‐week course</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia: MMSE; DSM‐IV; NICDS‐ADRDA</p> <p>Agitation: CMAI</p> <p>Aggression: CMAI subscale</p> <p>Global: CGI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Netherlands</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Institutionalised, AD, VaD, and other dementias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valproate (n = 42)</p> <p>Placebo (n = 42)</p> <p>Sodium valproate 480 mg/day</p> <p>3‐week course</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia: MMSE; DSM‐IV; NINCDS‐ADRDA; Clinical Dementia Rating Scale</p> <p>Agitation: BPRS subset</p> <p>Aggression: Patel's method; SDAS‐9 subscale; CGI; GIP</p> <p>Global: CGI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentric, institutionalised; AD, VaD, and other dementias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valproic acid (n = 87)</p> <p>Placebo (n = 85)</p> <p>Divalproex sodium (delayed release); titrated to target dose of 20 mg/kg/day; median dose 1000 mg/day </p> <p>6‐week course</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia: MMSE; DSM‐IV</p> <p>Agitation: CMAI</p> <p>Aggression: CMAI subscale</p> <p>Global: CGI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentric, institutionalised, AD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Divalproex (n = 48)</p> <p>Placebo (n = 78)</p> <p>Titrated to target dose 750 mg/day</p> <p>6‐week course</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia (probable or possible): NINDCDS‐ADRDA</p> <p>Agitation, hostility, and unco‐operativeness: BPRS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression Scale; CMAI: Cohen‐Mansfield Agitation Inventory; DSM‐IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GIP: Behavior Observation Scale of Intramural Psychogeriatric Patients; MMSE: Mini‐Mental State Examination; n: number of participants; NINDCDS‐ADRDA: National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association; SDAS‐9: 9‐item Social Dysfunction and Agitation Scale; VaD: vascular dementia. </p> </div> </div> <p>All studies included participants with dementia, mostly with moderate‐to‐severe dementia. All studies used one or more standard methods to diagnose dementia, including Alzheimer's disease, vascular dementia, and mixed dementia (DSM‐IV (<a href="./references#CD003945-bbs2-0026" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington (DC): American Psychiatric Publishing, 1994. ">APA 1994</a>); National Institute of Neurological and Communicative Disorders and Stroke‐Alzheimer's Disease and Related Disorders Association (NINCDS‐ADRDA; <a href="./references#CD003945-bbs2-0044" title="McKhannG , BrackmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA workgroup under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34:939‐44. ">McKhann 1984</a>)). </p> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> used the Clinical Dementia Rating Scale (<a href="./references#CD003945-bbs2-0039" title="HughesCP , BergL , DanzigerWL , CohenLA , MartinRL . A new clinical scale for the staging of dementia. British Journal of Psychiatry1982;140:566‐72. ">Hughes 1982</a>), in which 2/42 participants were classified as "light," 24/42 participants as "moderate," and 14/42 participants as "severe." This same study used the MMSE (<a href="./references#CD003945-bbs2-0036" title="FolsteinMF , FolsteinSE , McHughPR . A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189‐98. ">Folstein 1975</a>), but 14 participants could not be scored because of low level of function. All other studies also used the MMSE. Mean scores at baseline were 7.4 (<a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>), 6.8 (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>), 4.5 (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>), and 10.8 (range 4 to 24) (<a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). </p> <p>Inclusion criteria relating to degree of agitated behaviour varied between studies, but all studies required included participants to exhibit minimum levels of agitation according to standardised measures (Neuropsychiatric Inventory (NPI), BPRS, Social Dysfunction and Aggression Scale‐9). </p> <p> <ul id="CD003945-list-0006"> <li> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> required participants to display "significant BPSD" as indicated by a score of 8 or greater on the NPI. </p> </li> <li> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> required participants to have exhibited agitated behaviour for a minimum of two weeks "with sufficient intensity" to result in a BPRS score of three or more on items relating to tension, hostility, unco‐operativeness, or excitement. </p> </li> <li> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> used Patel's criteria for aggressive behaviour (<a href="./references#CD003945-bbs2-0051" title="PatelV , HopeT . Aggressive behavior in elderly people with dementia: a review. International Journal of Geriatric Psychiatry1993;8:457‐72. ">Patel 1993</a>), and also required participants to score 3 or greater on at least one item of the Social Dysfunction and Aggression Scale‐9. </p> </li> <li> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> included participants who exhibited "manic symptoms" according to the Bech‐Rafaelsen Mania Scale (BRMS) and six items of the BPRS. Participants were required to score 15 or greater on the BRMS and 3 or greater on two or more of the items of the BPRS relating to tension, grandiosity, hostility, suspiciousness, unco‐operativeness, and excitement, with a total score of 15 or more. </p> </li> <li> <p><a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> required participants to have at least a two‐week history of agitation with a total score greater than 2 on the BPRS items relating to tension, hostility, unco‐operativeness, or excitement. </p> </li> </ul> </p> </section> <section id="CD003945-sec-0075"> <h5 class="title">Interventions</h5> <section id="CD003945-sec-0076"> <h6 class="title">Divalproex sodium</h6> <p>One study treated participants with divalproex sodium delayed‐release tablets or placebo (<a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>). Dosage started at 125 mg twice daily and was titrated to 20 mg/kg/day to 30 mg/kg/day, to be reduced if intolerable adverse effects appeared. The median dose for treated participants at the end of six weeks was 1000 mg/day. One study treated participants with rapid‐acting divalproex sodium at an initial dose of 375 mg/day which was titrated upwards to a mean dose of 826 mg/day (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>). In this trial, a non‐blinded supervising physician, who had no contact with the blinded researchers, altered drug dosage by 125 mg/day, depending on written reports by the researchers of response and adverse effects. In <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>, participants commenced sprinkle formulation divalproex sodium 125 mg twice daily for three days, which was increased in 125 mg increments every three days to 750 mg/day or up to a maximum dose 1000 mg/day. Researchers decreased the dose by 125 mg/day if a participant experienced adverse effects. The mean dose at the end of the treatment period was 800 mg/day. </p> </section> <section id="CD003945-sec-0077"> <h6 class="title">Sodium valproate</h6> <p>In <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>, study participants received sodium valproate 240 mg twice daily for three weeks. Participants in <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> received valproate 125 mg liquid suspension twice daily, increased to 500 mg twice daily over the first two weeks. The dose could then be increased to a maximum of 1500 mg/day or decreased based on efficacy and tolerability as determined by a blinded study physician. </p> <p>All studies permitted short‐term use of short‐acting psychotropics. <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> used chloral hydrate. <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> permitted short‐term use of lorazepam, oxazepam, or chloral hydrate as needed. <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> allowed oxazepam for severe anxiety or insomnia. <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> permitted zolpidem or lorazepam (or both) for severe agitation or sleep‐induction. <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> permitted loxapine as a rescue medication. </p> </section> </section> <section id="CD003945-sec-0078"> <h5 class="title">Outcomes</h5> <p>All included studies aimed to assess the effect of valproate treatments on agitation, aggression, mania, and overall function of people with dementia. </p> <p>The instruments used to measure the outcomes in each study are given in <a href="#CD003945-tbl-0003">Table 2</a>. </p> <div class="table" id="CD003945-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes, instruments, and studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Instruments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>Agitation and aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CMAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS or agitation and hostility subscale, or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropsychiatric Inventory (NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social Dysfunction and Aggression‐9 Scale (SDAS‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global Impression Scale (CGI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nurse Observation Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patel's Method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overt Aggression Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other types of disturbed behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavior Scale for Intramural Psychogeriatric Patients (GIP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Functional performance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PSMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall clinical impression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of Adverse Reactions (checklist)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART 1989)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPRS: Brief Psychiatric Rating Scale; CMAI: Cohen‐Mansfield Agitation Inventory; MMSE: Mini‐Mental State Examination; PSMS: Physical Self‐Maintenance Scale. </p> </div> </div> <section id="CD003945-sec-0079"> <h6 class="title">Agitation and aggression</h6> <p>The included studies used several different scales to assess change in agitated and aggressive behaviour. </p> <p>Four studies used the CMAI scale to measure agitation and aggression (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). It was not clear which version of the CMAI was used, although three gave the same source reference for the scale (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> stated that they used a 36‐item version of CMAI, whereas the most commonly used version is the 29‐item version. Information obtained from the author suggested that they actually used the 29‐item version of the scale. <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> and <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> did not state specifically which version of the CMAI they used in their studies. We attempted to contact these authors to clarify the scale version and scoring used. <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> used a different version of the scale specifically designed for nursing home residents (<a href="./references#CD003945-bbs2-0031" title="Cohen‐MansfieldJ , WernerP , MarxMS . An observational study of agitation in agitated nursing home residents. International Psychogeriatrics1989;1:153‐65. ">Cohen‐Mansfield 1989</a>). </p> <p>Three studies used the BPRS to assess disturbed behaviour (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>), and two studies also used the agitation and hostility subscales of the BPRS as outcome measures (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). All three studies used the 18‐item scale but two studies rated items 0 to 6 (<a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>), whereas one study rated items 1 to 7 (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>). While this would lead to disparity in total scores in each study, analysis of change in score in each study were still comparable. Information relating to the scoring of the agitation and hostility subscales of the BPRS was not available from the authors of the studies which used them, and could not be found through a further literature search. </p> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> used the BRMS to assess manic symptoms. <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> used the OAS to measure aggression. <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> used the NPI and its agitation subscale at their primary outcome measure. <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> used the Social Dysfunction and Aggression‐9 Scale (SDAS‐9), and the "Nurse Observation" scale, to measure incidence of aggression; the CGI to rate clinical impression of aggressive behaviour; and GIP to measure other types of disturbed behaviour. </p> <p> <ul id="CD003945-list-0007"> <li> <p>The CMAI examines 29 types of agitated behaviour, including pacing, verbal or physical aggression, screaming, and restlessness. The frequency of these behaviours is measured on a 29‐item scale with each item rated from 0 (never occurs) to 6 (occurs several times an hour) and scores for physical and verbal aggression and overall aggression may be aggregated. </p> </li> <li> <p>The BPRS measures physical and verbal aggression, hallucinatory behaviour, and abnormal thought content. The scale comprises 18 items each scored on a 7‐point scale with a higher score indicating higher level of dysfunction. </p> </li> <li> <p>The CGI uses a 7‐point scale with scores ranging from 1 (no aggressive behaviour) to 7 (severely aggressive behaviour). It is also used to measure overall response to treatment. </p> </li> <li> <p>The BRMS is an 11‐item observer‐based scale that rates the severity of manic symptoms on a 5‐point scale (<a href="./references#CD003945-bbs2-0027" title="BechP , RafaelsonOJ , KramptP , BolwigTG . The mania rating scale: scale construction and inter‐observer agreement. Neuropharmacology1978;17:430‐1. ">Bech 1978</a>). </p> </li> <li> <p>The OAS quantifies aggressive verbal and physical behaviours and includes the number, specific nature, and intervention response. </p> </li> <li> <p>The NPI is a 12‐item scale, designed to assess the severity and frequency of behavioural symptoms in people with dementia (<a href="./references#CD003945-bbs2-0034" title="CummingsJL , MegaM , GrayK , Rosenberg‐ThompsonS , CarusiDA , GornbeinJ . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology1994;44:2308‐14. ">Cummings 1994</a>). </p> </li> <li> <p>The SDAS‐9 measures several aspects of behaviour to do with patient interaction with other people, and physical and verbal aggression. The scale is a 9‐point observation scale covering outward aggressive behaviour, with total sores ranging from 0 to 36). </p> </li> <li> <p>The "Nurse Observation" scale assesses the incidence of aggressive behaviour at the moment the behaviour occurs. </p> </li> <li> <p>The GIP consists of 14 observational scales to describe agitated and aggressive behaviour.</p> </li> </ul> </p> </section> <section id="CD003945-sec-0080"> <h6 class="title">Cognition</h6> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; and <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> assessed cognitive functioning using the MMSE. </p> <section id="CD003945-sec-0081"> <p><b>Functional <i>p</i>erformance</b></p> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> and <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> assessed participants' functional performance using the Physical Self‐Maintenance Scale (PSMS) (<a href="./references#CD003945-bbs2-0040" title="LawtonMP , BrodyEM . Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist1969;9:179‐86. ">Lawton 1969</a>). </p> </section> <section id="CD003945-sec-0082"> <p><b>Overall clinical impression</b></p> <p>Three studies included a rating of global clinical response of the participants using the CGI, a 7‐point scale with scores ranging from "very much improved" to "very much worse" (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> reported this as mean change and <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> as number of participants showing improvement. <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> reported CGI separately for therapeutic effect and adverse effects using a different Likert type scale for each. </p> </section> </section> <section id="CD003945-sec-0083"> <h6 class="title">Adverse effects</h6> <p>All five studies examined the tolerability, adverse effects, and safety of valproate preparations. </p> <p> <ul id="CD003945-list-0008"> <li> <p>Four studies used check‐lists of adverse effects (e.g. drowsiness, nausea, vomiting, diarrhoea, confusion, disturbance in speech, disturbance of co‐ordination, tremor, seizures, oedema, fever thrombocytopenia), which were reviewed at regular intervals by interviewing participants and nursing staff; and by reviewing chart entries (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). </p> </li> <li> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> measured adverse events based on the Coding Symbols for Thesaurus of Adverse Reaction Terms (<a href="./references#CD003945-bbs2-0033" title="COSTART: Coding Symbols Thesaurus for Adverse ReactionTerms . US Food and Drug Administration. 3. Rockville (MD): US Food and Drug Administration: Center for Drugs and Biologics, Division of Drug and Biological Products Experience, 1989. ">COSTART 1989</a>). </p> </li> </ul> </p> <section id="CD003945-sec-0084"> <p><b>Effect on carers (carers psychological morbidity)</b></p> <p>None of the included studies assessed any aspect of carer burden or well‐being.</p> </section> </section> </section> </section> <section id="CD003945-sec-0085"> <h4 class="title">Excluded studies</h4> <p>We excluded most studies on the basis of the study design (e.g. not RCTs). The studies that were excluded, with reasons for exclusion, are listed in the <a href="./references#CD003945-sec-0123" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD003945-sec-0086"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD003945-fig-0001">Figure 1</a>. </p> <section id="CD003945-sec-0087"> <h4 class="title">Allocation</h4> <p>All studies included in this review indicated that participants were randomly allocated to treatments groups. However, four studies did not report the process of random sequence generation and we considered them to be at unclear risk of bias in this domain (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>). For three of these studies, there was also no specific information about allocation concealment, but <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> stated that the "code was not available to the investigators" and so we rated its risk of bias due to allocation concealment to be low. <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> had a low risk of allocation bias. </p> </section> <section id="CD003945-sec-0088"> <h4 class="title">Blinding</h4> <p>Two studies failed to state explicitly whether all staff involved in the study were blind to the treatment allocation of the participants (unclear risk of bias; <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>), and two failed to state whether research staff completing the outcome measures were blinded (unclear risk of bias; <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>). </p> <p>In <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>, although the physicians having direct responsibility for participant care and researchers completing study assessments were blinded, a non‐blinded physician, who had no direct contact with these physicians, adjusted divalproex sodium dosage based on reports from the blinded raters. Similarly, in <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>, a pharmacist and independent physician reviewed out‐of‐range laboratory results, including valproate levels. These staff had no contact with participants, investigators, the ward team or participant's relatives so we considered that the risk of introducing bias due to unblinding was low. </p> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> was described as a double‐blind study but total serum valproate levels were measured weekly and monitored by nursing staff. It was not stated whether these nursing staff were involved in the study, so we judged this to pose an unclear risk of performance bias. </p> </section> <section id="CD003945-sec-0089"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>, 54% of the valproate‐treated participants dropped out compared with 29% of control participants; 22% of all participants dropped out because of adverse effects, and the study had to be discontinued prematurely. Further, since participants had been on therapy for varying periods of time when the study was terminated, interpretation of the effects of treatment was difficult. We considered this study at high risk of attrition bias. </p> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> included data in the analysis from participants who dropped out of the study, and gave the reasons for the participants dropping out (two from the divalproex group, and four from the placebo group; low risk of attrition bias). </p> <p>In <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>, 11/75 participants in the divalproex group and 14/78 participants in the placebo group dropped out of treatment early, but the reasons for discontinuation were not given. However, all participants who discontinued prematurely completed final assessments which were included in the analysis, so we considered the risk of attrition bias to be low. </p> <p>In <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>, two participants dropped out during each treatment phase but reasons for this were not stated. The study authors stated that they conducted an intention‐to‐treat analysis, but data for all participants was not included in the results table. We included only the results from the first part of the study in this review and obtained first‐phase data from the study authors for all participants; for this reason, we considered the risk of attrition bias to be low. </p> <p>In <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>, three participants dropped out of the study due to adverse events in either the placebo or washout periods and these data were included in the analysis. One participant was excluded from the analysis due to protocol violation (low risk of attrition bias). </p> </section> <section id="CD003945-sec-0090"> <h4 class="title">Selective reporting</h4> <p>We found no published protocols for the included studies. However, for all included studies, the results of the primary and secondary outcome measures that were specified in the methods sections of the papers were reported, as well as the frequency of adverse events. Therefore, we judged all the studies to be at low risk of selective reporting bias. </p> </section> <section id="CD003945-sec-0091"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> had a cross‐over design. No results from the first phase of the study were available. The statistical analysis did not take account of the paired nature of the data ("the t‐test for independent samples is used to analyse the two‐period cross‐over trial"). </p> <p>We noted that three of the included studies were supported by grants from Abbott laboratories – a company which may have had a vested interest in the efficacy of the treatment – but we did not rate this as a source of bias (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). </p> </section> </section> <section id="CD003945-sec-0092"> <h3 class="title" id="CD003945-sec-0092">Effects of interventions</h3> <p>See: <a href="./full#CD003945-tbl-0001"><b>Summary of findings for the main comparison</b> Valproate preparations compared to placebo for agitation in dementia</a> </p> <p>The included studies varied in the type of valproic acid preparation, dosage, and duration of therapy. The methods of evaluating the participants also varied between the studies, with use of different scales to assess agitation and aggression, and response to therapy. <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> was discontinued due to the disproportionate number of dropouts in the treatment group (54%) as well as a high proportion in the placebo group (29%), with the results that not all participants received treatment for the full study period. Many of these dropouts occurred in the first three weeks (11/47 participants). Due to the high risk of attrition bias caused by the high dropout rate, we decided to exclude the data from the pooled analysis in this review. <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> was a cross‐over design and first‐phase data were not available from the published paper, or from the authors, and so data from this study was also not included in our analyses. </p> <section id="CD003945-sec-0093"> <h4 class="title">Agitation and aggression</h4> <p>We were able to pool data on agitation/aggression measured with the BPRS from two studies and the CMAI from three studies. </p> <p>A meta‐analysis of agitated behaviour, assessed with total BPRS scores in two studies, showed that there was probably no difference between valproate and placebo group in total BPRS after six weeks of treatment (MD 0.23, 95% CI –2.14 to 2.59; 202 participants, 2 studies; <a href="./references#CD003945-fig-0003" title="">Analysis 1.1</a>; moderate‐quality evidence, downgraded due to imprecision) (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). A pooled analysis of agitation measured with the agitation factor of the BPRS confirmed that there was probably no effect of treatment specifically on agitation (MD –0.67, 95% CI –1.49 to 0.15; 202 participants, 2 studies; <a href="./references#CD003945-fig-0004" title="">Analysis 1.2</a>; moderate‐quality evidence, downgraded due to imprecision). The quality of evidence on agitation measured with the CMAI was lower, but meta‐analysis of three studies that reported the change in total CMAI score between baseline and six weeks also suggested no effect on agitated behaviour (MD –1.84, 95% CI –6.02 to 2.34, 217 participants, 3 studies; I<sup>2</sup> = 52%; <a href="./references#CD003945-fig-0005" title="">Analysis 1.3</a>; very low‐quality evidence, downgraded due to risk of bias, inconsistency, and imprecision) (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> and <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> did not state specifically which version of the CMAI they used in their studies, we made the assumption that they used the standard 29‐item scale. Information from <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> indicated that they also used the 29 item scale despite the paper stating they used a 36 item version of the scale. In light of the uncertainty regarding which version <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> used, we repeated the pooled analysis of change in total CMAI score after excluding data from <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> (MD 1.96, 95% CI –6.18 to 10.10; 70 participants, 2 studies; very low‐quality evidence, downgraded due to risk of bias, inconsistency, and imprecision). </p> <p>Single studies only reported the other outcome measures. <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> found that there was probably little or no effect of divalproex on the hostility factor of the BPRS (MD 0.10, 95% CI –1.12 to 1.32; 55 participants, 1 study; <a href="./references#CD003945-fig-0006" title="">Analysis 1.4</a>; moderate‐quality evidence, downgraded due to imprecision) or the Overt aggression total score (MD 0.10, 95% CI –3.42 to 3.62; 55 participants, 1 study; <a href="./references#CD003945-fig-0007" title="">Analysis 1.5</a>; moderate‐quality evidence, downgraded due to imprecision). <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> used the NPI. This showed a clinically important difference in behavioural symptoms as measured by the NPI total score, favouring the placebo group, but there was a great deal of uncertainty about this result (MD 15.28, 95% CI ‐5.19 to 35.75; 14 participants, 1 study; <a href="./references#CD003945-fig-0008" title="">Analysis 1.6</a>; very low‐quality evidence, downgraded one level due to risk of bias and two levels due to imprecision). There was similarly a high level of uncertainty about the result on the NPI agitation/aggression subscale, which showed no clear evidence of a difference between groups (MD 1.43, 95% CI –2.48 to 5.34; 14 participants, 1 study; <a href="./references#CD003945-fig-0009" title="">Analysis 1.7</a>; very low‐quality evidence, downgraded one level due to risk of bias and two levels due to imprecision). </p> </section> <section id="CD003945-sec-0094"> <h4 class="title">Cognition</h4> <p>Three studies assessed cognitive functioning using the MMSE (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). The quality of this evidence was very low. but pooled analysis of the data indicated that there may have been little or no effect of valproate on the change in MMSE score over the six‐week treatment period (MD –0.70, 95% CI –1.61 to 0.20; 217 participants, 3 studies; <a href="./references#CD003945-fig-0010" title="">Analysis 1.8</a>; very low‐quality evidence, downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> <section id="CD003945-sec-0095"> <h4 class="title">Functional performance</h4> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> and <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> assessed functional ability using the PSMS. Pooled analysis of the change in total PSMS score indicated that there was probably little or no effect of valproate on this outcome (MD 1.19, 95% CI 0.40 to 1.98; 203 participants, 2 studies; <a href="./references#CD003945-fig-0011" title="">Analysis 1.9</a>; moderate‐quality evidence, downgraded due to imprecision). </p> </section> <section id="CD003945-sec-0096"> <h4 class="title">Overall clinical impression</h4> <p>Three studies included a measure of global clinical change, but we excluded data from <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> due to the very high risk of attrition bias. <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> used the CGI as an index of clinical efficacy, measuring change in participants' overall clinical condition on a 7‐point scale (0 marked improvement to 6 marked worsening). The number of participants showing improvement was reported not to differ significantly between the two groups. <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> used the CGI to rate "therapeutic effect" on a 4‐point scale, and the presence and clinical significance of adverse effects on a 7‐point scale (from very much improved to very much worse). They reported no difference between groups in CGI ratings. Because of the different ways in which the CGI was used was used in these two studies, we were unable to pool data. </p> </section> <section id="CD003945-sec-0097"> <h4 class="title">Incidence and severity of adverse effects</h4> <p>Meta‐analysis of three studies, all of which used divalproex sodium, found there may have been a higher rate of adverse effects among participants treated with divalproex sodium than among participants in the control group (OR 2.02, 95% CI 1.30 to 3.14; 381 participants, 3 studies; <a href="./references#CD003945-fig-0038" title="">Analysis 2.27</a>; low‐quality evidence, downgraded due to imprecision and inconsistency) (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>). A fourth study reported that the mean incidence of adverse effects was low during three weeks of observation in both sodium valproate (0.17) and placebo (0.02) groups, but the study provided no description of the types of adverse reactions or actual numbers of adverse events experienced, so we could not include this study in the meta‐analysis (<a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>). Data on adverse effects during the first treatment phase of <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> were not available in the published data or from the authors, but over the course of both treatment phases, 12 participants experienced at least one adverse event while taking valproate compared to eight participants while taking placebo. The mean number of adverse events from valproate was significantly greater than with placebo. </p> <p>The descriptions of adverse effects which study authors used varied making pooled analysis of all adverse effects difficult. However, pooled analysis of adverse effects that were reported in more than one study indicated that sedation (OR 2.66, 95% CI 1.44 to 4.92; 228 participants, 2 studies; <a href="./references#CD003945-fig-0012" title="">Analysis 2.1</a>; moderate‐quality evidence, downgraded due to imprecision), 'nausea, vomiting and diarrhoea' (OR 6.92, 95% CI 2.13 to 22.49; 381 participants, 3 studies; <a href="./references#CD003945-fig-0013" title="">Analysis 2.2</a>; moderate‐quality evidence, downgraded due to imprecision), and UTIs (OR 3.07, 95% CI 1.05 to 8.97; 228 participants, 2 studies; <a href="./references#CD003945-fig-0014" title="">Analysis 2.3</a>; moderate‐quality evidence, downgraded due to imprecision) were more frequently reported among valproate‐treated participants than placebo‐treated participants. Falls, respiratory, skin or joint problems, and infections (other than UTI) were no more frequent in valproate‐treated than in placebo‐treated participants. </p> <p>One study reported thrombocytopenia in 6/87 participants in the valproate group and 0/85 participants in the placebo group (<a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>). One study reported thrombocytopenia in 2/14 participants during the treatment phase and none in the placebo phase (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>). In <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>, 2/28 participants in the divalproex group had developed a significant decrease in platelet count, but not to the level of thrombocytopenia. <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> monitored blood counts, but reported no instances of a drop in platelet count. </p> <section id="CD003945-sec-0098"> <h5 class="title">Serious adverse events</h5> <p>The included studies varied in the reporting of serious adverse events (SAE) during their treatment period. <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> did not report the incidence of SAE during their study. <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> did not report numbers of participants who experienced SAE clearly, but the study stated that two participants in the treatment phase had falls that rated as SAEs. There was no indication given about whether these falls were considered related to the study medication and it was not clear whether these were the only SAEs to occur. <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> also did not report specifically on numbers of SAEs although there was one death in the drug‐treatment group which was not considered related to the study drug. The authors stated that most adverse events were rated as mild to moderate in severity and were judged as not related to the study drug. <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> reported four SAEs, one in the placebo group (worsening of chronic renal failure) and three in the divalproex group (one with seizure, cerebrovascular accident, and pneumonia; one with seizure; and one with small bowel obstruction). <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> reported one SAE due to hyponatraemia in the divalproex group, which was thought probably to be related to the study drug. Six other participants experienced SAEs, five in the divalproex group and one in the placebo group. These SAEs were four hospitalisations (for cellulitis, dehydration, pneumonia, myocardial infarction, and constipation) and one cerebrovascular accident; all were considered to be unrelated to the study drug. </p> <p>Pooled analysis of the number of SAEs for the two studies which did report data indicated that participants treated with valproate were more likely to experience SAEs (OR 4.77, 95% CI 1.00 to 22.74; 228 participants, 2 studies; <a href="./references#CD003945-fig-0039" title="">Analysis 2.28</a>; very low‐quality evidence, downgraded due to risk of bias, inconsistency, and imprecision) (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>). </p> </section> </section> <section id="CD003945-sec-0099"> <h4 class="title">Dropouts</h4> <p>All included studies reported that there were participants who dropped out during the study period. For most studies, the number of dropouts were not disproportionate between the treatment and the placebo groups (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>: 7% divalproex versus 14% placebo; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>: 0% valproate versus 5% placebo; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>: 15% divalproex versus 18% placebo; <a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>: 7% valproate versus 7% placebo). However, in the study by <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>, a disproportionate number of participants in the treatment group dropped out of the study (54% divalproex versus 29% placebo), with 22% from the treatment group compared to only 4% of the placebo group withdrawing due to adverse events. These adverse events were predominantly related to somnolence but also included hyponatraemia, accidents, and weight loss. Due to this disproportionate level of withdrawal in the divalproex group, the study was terminated early. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003945-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003945-sec-0100"></div> <section id="CD003945-sec-0101"> <h3 class="title" id="CD003945-sec-0101">Summary of main results</h3> <p>We found no evidence of a beneficial effect of valproate on our primary outcome of agitation or closely related behavioural outcomes, measured using several outcome scales. Neither did we find evidence of any important effect on any of our secondary efficacy outcomes. However, participants taking valproate may have been at higher risk of adverse effects, including SAEs. These findings are described in <a href="./full#CD003945-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>Specifically, our results showed that there was probably little or no effect on agitated and aggressive behaviours as measured by the BPRS. There was very low‐quality evidence using other scales, but results were consistent with this finding. Pooled analysis also indicated probably slightly worse function in the valproate‐treated group, on functional ability assessed with the PSMS, of uncertain clinical importance. We found very low‐quality evidence of no effect on cognition assessed with the MMSE. </p> <p>Pooled analysis of the numbers of participants who experienced any adverse effect was limited to three of the included studies (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a>), but indicated that participants treated with valproate preparations may have been more likely to experience adverse effects than participants taking placebo. Likewise, participants treated with valproate preparations were more likely to experience SAEs, although the quality of this evidence was very low (data from two studies; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>). Individual adverse effects which were found in one or more studies to be more frequent in the valproate‐treated group were sedation, gastrointestinal symptoms, and UTI. </p> </section> <section id="CD003945-sec-0102"> <h3 class="title" id="CD003945-sec-0102">Overall completeness and applicability of evidence</h3> <p>The small number of included studies, some of which involved small numbers of participants, limited the evidence available. This was further limited since one study closed prematurely and that separate first‐phase data were not available from the cross‐over trials for inclusion in the review analysis (<a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> for some data; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>). </p> <p>Because of the limited number of participants, it was not possible to analyse secondary objectives such as the effect of valproate therapy on individual manifestations of agitation (e.g. crying out, wandering) or the influence of age, gender, or degree and type of dementia on the response to therapy. The small number of included studies also meant it was not possible to analyse how the response to valproate preparations was influenced by dose and duration of treatment. </p> <p>The premature termination of one study, in which 47 (54%) treated participants dropped out before the protocol could be completed, severely limited the confidence that could be placed on the conclusion of the study authors that divalproex sodium improved agitation of people with dementia (<a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>). Because so many of the participants did not complete the study treatment period, we did not include data from this study in the pooled efficacy analyses. </p> </section> <section id="CD003945-sec-0103"> <h3 class="title" id="CD003945-sec-0103">Quality of the evidence</h3> <p>We only identified five studies for inclusion in this review and most varied in the outcome measures used to assess impact of treatment with valproate preparations on agitated behaviour thus making comparisons of study outcomes difficult. We found the quality of evidence for most outcomes measures used to be of low or very low quality primarily due to risk of bias, imprecision, and inconsistency in the included studies (because of poorly described methodology, small sample sizes, and heterogeneity of sample groups and treatments used). </p> <p>Methodological and clinical diversity limited opportunities for pooling data. Specifically, variations in method, type of medication, dosage, duration of treatment, and use of different outcome measures in these studies made it difficult to apply meta‐analysis. For example, it was difficult to compare directly studies that employed short‐acting sodium valproate (<a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>) or longer‐acting divalproex sodium (<a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>), and in which the dosage varied more than two‐fold (<a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>, mean dose 480 mg/day; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>, median dose 1000 mg/day; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>, mean dose 875 mg/day). </p> <p>We did not include data from <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> because we could not obtain first period data as our protocol required. We considered that there was a risk of carryover effects. We also considered that there was a unit of analysis error in the analysis reported in the paper, which failed to account for the cross‐over design. </p> </section> <section id="CD003945-sec-0104"> <h3 class="title" id="CD003945-sec-0104">Potential biases in the review process</h3> <p>It is possible that pooling of clinically diverse studies may have concealed important benefits or harms. </p> </section> <section id="CD003945-sec-0105"> <h3 class="title" id="CD003945-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>The conclusions of this updated review were in keeping with the NICE evidence summary on the use of valproate preparations for agitation and aggression in dementia which stated that such medications were no more effective than placebo, and that adverse effects were more common in people taking them (<a href="./references#CD003945-bbs2-0047" title="National Institute for Health and Care Excellence. Management of Aggression, Agitation and Behavioural Disturbances in Dementia: Valproate Preparations. London: National Institute for Health and Care Excellence, 2015. ">NICE 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003945-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003945-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003945-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 1 Brief Psychiatric Rating Scale (BPRS) total score. Change from baseline at 6 weeks (intention to treat (ITT))." data-id="CD003945-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 1 Brief Psychiatric Rating Scale (BPRS) total score. Change from baseline at 6 weeks (intention to treat (ITT)). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 2 BPRS agitation factor. Change from baseline at 6 weeks (ITT)." data-id="CD003945-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 2 BPRS agitation factor. Change from baseline at 6 weeks (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 3 Cohen‐Mansfield Agitation Index. Total Score. Change from baseline at 6 weeks (ITT)." data-id="CD003945-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 3 Cohen‐Mansfield Agitation Index. Total Score. Change from baseline at 6 weeks (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 4 BPRS hostility factor. Change from baseline at 6 weeks (ITT)." data-id="CD003945-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 4 BPRS hostility factor. Change from baseline at 6 weeks (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 5 Overt Aggression Scale total score. Change from baseline at 6 weeks (ITT)." data-id="CD003945-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 5 Overt Aggression Scale total score. Change from baseline at 6 weeks (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 6 Neuropsychiatric Inventory total score. Change from baseline at 6 weeks (ITT)." data-id="CD003945-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 6 Neuropsychiatric Inventory total score. Change from baseline at 6 weeks (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 7 Neuropsychiatric Inventory Agitation/Aggression subscore. Change from baseline at 6 weeks (ITT)." data-id="CD003945-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 7 Neuropsychiatric Inventory Agitation/Aggression subscore. Change from baseline at 6 weeks (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 8 Mini‐Mental State Examination total score. Change from baseline at 6 weeks (ITT)." data-id="CD003945-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 8 Mini‐Mental State Examination total score. Change from baseline at 6 weeks (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate preparations versus placebo, Outcome 9 Physical Self‐Maintenance Scale total score. Change from baseline at 6 weeks (ITT)." data-id="CD003945-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Valproate preparations versus placebo, Outcome 9 Physical Self‐Maintenance Scale total score. Change from baseline at 6 weeks (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 1 Total number of participants with sedation at 6 weeks." data-id="CD003945-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 1 Total number of participants with sedation at 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 2 Total number of participants with nausea, vomiting, or diarrhoea at 6 weeks." data-id="CD003945-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 2 Total number of participants with nausea, vomiting, or diarrhoea at 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 3 Total number of participants with a urinary tract infection by 6 weeks." data-id="CD003945-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 3 Total number of participants with a urinary tract infection by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 4 Total number of participants who had falls by 6 weeks." data-id="CD003945-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 4 Total number of participants who had falls by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 5 Total number of participants with general disorders by 6 weeks." data-id="CD003945-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 5 Total number of participants with general disorders by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 6 Total number of participants with postural instability by 6 weeks." data-id="CD003945-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 6 Total number of participants with postural instability by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 7 Total number of participants with weakness by 6 weeks." data-id="CD003945-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 7 Total number of participants with weakness by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 8 Total number of participants with cardiovascular problems by 6 weeks." data-id="CD003945-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 8 Total number of participants with cardiovascular problems by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 9 Total number of participants with oedema by 6 weeks." data-id="CD003945-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 9 Total number of participants with oedema by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 10 Total number of participants with a fever by 6 weeks." data-id="CD003945-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 10 Total number of participants with a fever by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 11 Total number of participants with a respiratory problem by 6 weeks." data-id="CD003945-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 11 Total number of participants with a respiratory problem by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 12 Total number of participants with ataxia at 6 weeks." data-id="CD003945-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 12 Total number of participants with ataxia at 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 13 Total number of participants with a skin problem at 6 weeks." data-id="CD003945-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 13 Total number of participants with a skin problem at 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 14 Total number of participants with trauma (other than falls) by 6 weeks." data-id="CD003945-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 14 Total number of participants with trauma (other than falls) by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 15 Total number of participants with thrombocytopenia by 6 weeks." data-id="CD003945-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 15 Total number of participants with thrombocytopenia by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 16 Total number of participants with joint problems by 6 weeks." data-id="CD003945-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 16 Total number of participants with joint problems by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 17 Total number of participants with other infection by 6 weeks." data-id="CD003945-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 17 Total number of participants with other infection by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 18 Total number of participants with hallucinations by 6 weeks." data-id="CD003945-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 18 Total number of participants with hallucinations by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 19 Total number of participants with accidental injury by 6 weeks." data-id="CD003945-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 19 Total number of participants with accidental injury by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 20 Total number of participants with anorexia by 6 weeks." data-id="CD003945-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 20 Total number of participants with anorexia by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 21 Total number of participants with weight loss by 6 weeks." data-id="CD003945-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 21 Total number of participants with weight loss by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 22 Total number of participants with dehydration by 6 weeks." data-id="CD003945-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 22 Total number of participants with dehydration by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 23 Total number of participants with metabolism and nutritional disorders by 6 weeks." data-id="CD003945-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 23 Total number of participants with metabolism and nutritional disorders by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 24 Total number of participants with psychiatric disorders by 6 weeks." data-id="CD003945-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 24 Total number of participants with psychiatric disorders by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 25 Total number of participants with other gastrointestinal problem by 6 weeks." data-id="CD003945-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 25 Total number of participants with other gastrointestinal problem by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 26 Total numbers of participants with nervous system disorders by 6 weeks." data-id="CD003945-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 26 Total numbers of participants with nervous system disorders by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 27 Total number of participants with any adverse event by 6 weeks." data-id="CD003945-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 27 Total number of participants with any adverse event by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003945-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/urn:x-wiley:14651858:media:CD003945:CD003945-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_t/tCD003945-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Divalproex versus placebo, Outcome 28 Total number of participants with serious adverse events by 6 weeks." data-id="CD003945-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Divalproex versus placebo, Outcome 28 Total number of participants with serious adverse events by 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/media/CDSR/CD003945/image_n/nCD003945-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003945-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Valproate preparations compared to placebo for agitation in dementia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Valproate preparations compared to placebo for agitation in dementia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with agitation in dementia<br/> <b>Setting:</b> <br/> <b>Intervention:</b> valproate preparations<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with valproate preparations</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Agitation and aggression</b><br/> assessed with: Brief Psychiatric Rating Scale total score. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 0–108 (higher score indicated higher level of dysfunction)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for agitation and aggression was –5.34 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.23 higher<br/> (2.14 lower to 2.59 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Agitation and aggression</b><br/> assessed with: BPRS agitation factor. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 0–18 (higher score indicated higher level of dysfunction)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for agitation and aggression was –1.88 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.67 lower<br/> (1.49 lower to 0.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Agitation and aggression</b><br/> assessed with: Cohen‐Mansfield Agitation Index total score. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 0–216 (higher score indicated more agitated behaviour)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for agitation and aggression was –4.42 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.84 lower<br/> (6.02 lower to 2.34 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition</b><br/> assessed with: Mini‐Mental State Examination total score. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 0–30 (lower score indicated greater cognitive impairment)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for cognition was 0.46 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.7 lower<br/> (1.61 lower to 0.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional performance</b><br/> assessed with: Physical Self‐Maintenance Scale total score. Change from baseline at 6 weeks (ITT) </p> <p>Scale: 6–30 (higher score indicated greater impairment in ADL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline for functional performance was 0.06 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.19 higher<br/> (0.4 higher to 1.98 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Any adverse event</b> by 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 2.02</b><br/> (1.30 to 3.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>381<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>602 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>753 per 1000<br/> (663 to 826) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> by 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 4.77</b><br/> (1.00 to 22.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/> (18 to 291) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADL:</b> activities of daily living; <b>CI:</b> confidence interval; <b>ITT:</b> intention to treat; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision due to small number of participants. </p> <p><sup>b</sup>Downgraded in light of imprecision due to confidence intervals including the potential for harm or benefit. </p> <p><sup>c</sup>Downgraded one level due to inconsistency (heterogeneity between studies). </p> <p><sup>d</sup>Downgraded one level due to study limitations (risk of bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Valproate preparations compared to placebo for agitation in dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003945-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% Women</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnoses and baseline assessments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean MMSE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentric, institutionalised; Alzheimer's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valproate (n = 14)</p> <p>Placebo (n = 13)</p> <p>Valproate titrated to 1500 mg/day</p> <p>6‐week course</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD: NINDCDS‐ADRDA criteria</p> <p>Agitation/aggression: CMAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentric, institutionalised; AD, VaD, and other dementias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valproic acid (n = 28)</p> <p>Placebo (n = 28).</p> <p>Divalproex sodium titrated to mean 826 mg/day</p> <p>6‐week course</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia: MMSE; DSM‐IV; NICDS‐ADRDA</p> <p>Agitation: CMAI</p> <p>Aggression: CMAI subscale</p> <p>Global: CGI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Netherlands</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Institutionalised, AD, VaD, and other dementias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valproate (n = 42)</p> <p>Placebo (n = 42)</p> <p>Sodium valproate 480 mg/day</p> <p>3‐week course</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia: MMSE; DSM‐IV; NINCDS‐ADRDA; Clinical Dementia Rating Scale</p> <p>Agitation: BPRS subset</p> <p>Aggression: Patel's method; SDAS‐9 subscale; CGI; GIP</p> <p>Global: CGI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentric, institutionalised; AD, VaD, and other dementias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valproic acid (n = 87)</p> <p>Placebo (n = 85)</p> <p>Divalproex sodium (delayed release); titrated to target dose of 20 mg/kg/day; median dose 1000 mg/day </p> <p>6‐week course</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia: MMSE; DSM‐IV</p> <p>Agitation: CMAI</p> <p>Aggression: CMAI subscale</p> <p>Global: CGI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentric, institutionalised, AD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Divalproex (n = 48)</p> <p>Placebo (n = 78)</p> <p>Titrated to target dose 750 mg/day</p> <p>6‐week course</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia (probable or possible): NINDCDS‐ADRDA</p> <p>Agitation, hostility, and unco‐operativeness: BPRS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression Scale; CMAI: Cohen‐Mansfield Agitation Inventory; DSM‐IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GIP: Behavior Observation Scale of Intramural Psychogeriatric Patients; MMSE: Mini‐Mental State Examination; n: number of participants; NINDCDS‐ADRDA: National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association; SDAS‐9: 9‐item Social Dysfunction and Agitation Scale; VaD: vascular dementia. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003945-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes, instruments, and studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Instruments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>Agitation and aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CMAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS or agitation and hostility subscale, or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropsychiatric Inventory (NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social Dysfunction and Aggression‐9 Scale (SDAS‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global Impression Scale (CGI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nurse Observation Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patel's Method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overt Aggression Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other types of disturbed behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavior Scale for Intramural Psychogeriatric Patients (GIP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Functional performance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PSMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall clinical impression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of Adverse Reactions (checklist)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0001" title="HerrmannN , LanctotKL , RothenbergLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23:116‐9. ">Herrmann 2007</a>; <a href="./references#CD003945-bbs2-0002" title="PorsteinssonAP , TariotPN , ErbR , CoxC , SmithE , JakimovichL , et al. Placebo controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry2001;9(1):58‐66. ">Porsteinsson 2001</a>; <a href="./references#CD003945-bbs2-0003" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA . Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomised placebo controlled clinical trial. International Journal of Psychiatry2002;17(6):579‐85. ">Sival 2002</a>; <a href="./references#CD003945-bbs2-0005" title="TariotPN , RamanR , JakimovichL , SchneiderL , PorsteinssonA , ThomasR , et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Geriatric Psychiatry2005;13:942‐9. ">Tariot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART 1989)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003945-bbs2-0004" title="TariotPN , SchneiderLS , MintzerJE , CutlerAJ , CunninghamMR , ThomasMS , et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double‐blind, placebo‐controlled trial. Current Therapeutic Research2001;62(1):51‐67. ">Tariot 2001</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>BPRS: Brief Psychiatric Rating Scale; CMAI: Cohen‐Mansfield Agitation Inventory; MMSE: Mini‐Mental State Examination; PSMS: Physical Self‐Maintenance Scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes, instruments, and studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/full#CD003945-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003945-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Valproate preparations versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Brief Psychiatric Rating Scale (BPRS) total score. Change from baseline at 6 weeks (intention to treat (ITT)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐2.14, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 BPRS agitation factor. Change from baseline at 6 weeks (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.49, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cohen‐Mansfield Agitation Index. Total Score. Change from baseline at 6 weeks (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.84 [‐6.02, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 BPRS hostility factor. Change from baseline at 6 weeks (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐1.12, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Overt Aggression Scale total score. Change from baseline at 6 weeks (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐3.42, 3.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Neuropsychiatric Inventory total score. Change from baseline at 6 weeks (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.28 [‐5.19, 35.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Neuropsychiatric Inventory Agitation/Aggression subscore. Change from baseline at 6 weeks (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [‐2.48, 5.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mini‐Mental State Examination total score. Change from baseline at 6 weeks (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.61, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Physical Self‐Maintenance Scale total score. Change from baseline at 6 weeks (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.40, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Valproate preparations versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003945-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Divalproex versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of participants with sedation at 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [1.44, 4.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of participants with nausea, vomiting, or diarrhoea at 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.92 [2.13, 22.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total number of participants with a urinary tract infection by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [1.05, 8.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total number of participants who had falls by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.71, 2.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total number of participants with general disorders by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.05, 4.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total number of participants with postural instability by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.5 [0.47, 43.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Total number of participants with weakness by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.47 [0.54, 204.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Total number of participants with cardiovascular problems by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.18, 24.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Total number of participants with oedema by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.82 [0.39, 158.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total number of participants with a fever by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.82 [0.39, 158.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Total number of participants with a respiratory problem by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.33, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Total number of participants with ataxia at 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.28, 6.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Total number of participants with a skin problem at 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.55, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Total number of participants with trauma (other than falls) by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.10, 4.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Total number of participants with thrombocytopenia by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.64 [0.76, 245.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Total number of participants with joint problems by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.35, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Total number of participants with other infection by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.70, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Total number of participants with hallucinations by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.12, 79.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Total number of participants with accidental injury by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.84, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Total number of participants with anorexia by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.92, 6.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Total number of participants with weight loss by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [0.71, 10.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Total number of participants with dehydration by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [0.73, 18.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Total number of participants with metabolism and nutritional disorders by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [0.65, 16.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Total number of participants with psychiatric disorders by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.71, 3.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Total number of participants with other gastrointestinal problem by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.70, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Total numbers of participants with nervous system disorders by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.01, 5.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Total number of participants with any adverse event by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.30, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Total number of participants with serious adverse events by 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.77 [1.00, 22.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Divalproex versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003945.pub4/references#CD003945-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003945.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003945-note-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003945-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003945-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003945-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD003945-note-0006">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003945-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD003945-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003945-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003945\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003945\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003945\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003945\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003945\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003945.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003945.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003945.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003945.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003945.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728752967"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003945.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728752971"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003945.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecc26cb53f56f',t:'MTc0MDcyODc1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 